DE102022103658A1 - Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer - Google Patents
Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer Download PDFInfo
- Publication number
- DE102022103658A1 DE102022103658A1 DE102022103658.8A DE102022103658A DE102022103658A1 DE 102022103658 A1 DE102022103658 A1 DE 102022103658A1 DE 102022103658 A DE102022103658 A DE 102022103658A DE 102022103658 A1 DE102022103658 A1 DE 102022103658A1
- Authority
- DE
- Germany
- Prior art keywords
- tryptophan
- hydroxytryptophan
- composition according
- peripheral degradation
- peripheral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102022103658.8A DE102022103658A1 (de) | 2022-02-16 | 2022-02-16 | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
| JP2024548458A JP2025505294A (ja) | 2022-02-16 | 2023-02-08 | L-トリプトファン、l-5-ヒドロキシトリプトファンおよび末梢分解阻害剤を含む医薬組成物および医薬 |
| CN202380022428.3A CN118871096A (zh) | 2022-02-16 | 2023-02-08 | 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物 |
| AU2023222362A AU2023222362A1 (en) | 2022-02-16 | 2023-02-08 | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor |
| KR1020247030751A KR20240152875A (ko) | 2022-02-16 | 2023-02-08 | L-트립토판, l-5-하이드록시트립토판 및 말초 분해 억제제를 포함하는 약학 조성물 및 약제 |
| PCT/EP2023/053129 WO2023156275A1 (en) | 2022-02-16 | 2023-02-08 | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor |
| EP23704337.7A EP4479027A1 (en) | 2022-02-16 | 2023-02-08 | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor |
| CA3243635A CA3243635A1 (en) | 2022-02-16 | 2023-02-08 | PHARMACEUTICAL COMPOSITION AND MEDICINE COMPRISING L-TRYPTOPHAN, L-5-HYDROXYTRYPTOPHAN AND A PERIPHERAL DEGRADATION INHIBITOR |
| US18/839,100 US20250161270A1 (en) | 2022-02-16 | 2023-02-08 | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor |
| MX2024009966A MX2024009966A (es) | 2022-02-16 | 2024-08-14 | Composicion farmaceutica y medicamento que comprenden l-triptofano, l-5-hidroxitriptofano y un inhibidor de la degradacion periferica |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102022103658.8A DE102022103658A1 (de) | 2022-02-16 | 2022-02-16 | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102022103658A1 true DE102022103658A1 (de) | 2023-08-17 |
Family
ID=85221827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102022103658.8A Pending DE102022103658A1 (de) | 2022-02-16 | 2022-02-16 | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250161270A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4479027A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505294A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240152875A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118871096A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023222362A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243635A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE102022103658A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009966A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023156275A1 (cg-RX-API-DMAC7.html) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126672A (en) | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4167558A (en) | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| DE3232873A1 (de) | 1981-09-14 | 1983-03-31 | F. Hoffmann-La Roche & Co AG, 4002 Basel | Pharmazeutisches praeparat |
| WO1991007960A1 (fr) | 1989-11-24 | 1991-06-13 | Paul Trouillas | Compositions pharmaceutiques destinees au traitement de l'ataxie et les troubles de l'equilibre |
| EP0344158B1 (de) | 1986-12-13 | 1992-04-08 | KAMPRAD, Joachim | Schmerzpräparat |
| EP1784177B1 (de) | 2004-08-12 | 2009-04-29 | Dr. Kamprad Kg | Formulierung für l-tryptophan mit carbidopa/ benserazid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| EP1751312A4 (en) * | 2004-05-21 | 2010-01-27 | Univ Duke | POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS |
| US20060257469A1 (en) * | 2005-04-05 | 2006-11-16 | Bulka Yochanan R | Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase |
| ES2948788T3 (es) * | 2018-01-29 | 2023-09-19 | Univ Duke | Composiciones y métodos para mejorar la biodisponibilidad del 5-hidroxitriptófano |
-
2022
- 2022-02-16 DE DE102022103658.8A patent/DE102022103658A1/de active Pending
-
2023
- 2023-02-08 US US18/839,100 patent/US20250161270A1/en active Pending
- 2023-02-08 KR KR1020247030751A patent/KR20240152875A/ko active Pending
- 2023-02-08 AU AU2023222362A patent/AU2023222362A1/en active Pending
- 2023-02-08 CA CA3243635A patent/CA3243635A1/en active Pending
- 2023-02-08 EP EP23704337.7A patent/EP4479027A1/en active Pending
- 2023-02-08 JP JP2024548458A patent/JP2025505294A/ja active Pending
- 2023-02-08 WO PCT/EP2023/053129 patent/WO2023156275A1/en not_active Ceased
- 2023-02-08 CN CN202380022428.3A patent/CN118871096A/zh active Pending
-
2024
- 2024-08-14 MX MX2024009966A patent/MX2024009966A/es unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4126672A (en) | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4167558A (en) | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| DE3232873A1 (de) | 1981-09-14 | 1983-03-31 | F. Hoffmann-La Roche & Co AG, 4002 Basel | Pharmazeutisches praeparat |
| EP0344158B1 (de) | 1986-12-13 | 1992-04-08 | KAMPRAD, Joachim | Schmerzpräparat |
| WO1991007960A1 (fr) | 1989-11-24 | 1991-06-13 | Paul Trouillas | Compositions pharmaceutiques destinees au traitement de l'ataxie et les troubles de l'equilibre |
| EP1784177B1 (de) | 2004-08-12 | 2009-04-29 | Dr. Kamprad Kg | Formulierung für l-tryptophan mit carbidopa/ benserazid |
Non-Patent Citations (2)
| Title |
|---|
| SHAW, Kelly A.; TURNER, Jane; DEL MAR, Chris. Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database of Systematic Reviews, 2002, Nr. 1. |
| TURNER, Erick H.; BLACKWELL, Aaron D. 5-Hydroxytryptophan plus SSRIs for in-terferon-induced depression: synergistic mechanisms for normalizing synaptic seroto-nin. Medical hypotheses, 2005, 65. Jg., Nr. 1, S. 138-144. |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025505294A (ja) | 2025-02-21 |
| WO2023156275A1 (en) | 2023-08-24 |
| CA3243635A1 (en) | 2023-08-24 |
| EP4479027A1 (en) | 2024-12-25 |
| AU2023222362A1 (en) | 2024-09-12 |
| CN118871096A (zh) | 2024-10-29 |
| KR20240152875A (ko) | 2024-10-22 |
| US20250161270A1 (en) | 2025-05-22 |
| MX2024009966A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230240984A1 (en) | Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis | |
| EP0267321B1 (de) | Ibuprofen enthaltendes Arzneimittel | |
| JP4166951B2 (ja) | 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ | |
| JP2002518456A (ja) | 脳血管の正常状態を支持するための栄養補助食品 | |
| JP2001513487A (ja) | 糖尿病治療用組成物及び治療方法 | |
| Goole et al. | Levodopa delivery systems for the treatment of Parkinson's disease: an overview | |
| US5612061A (en) | Composition and method for the treatment of premenstrual syndrome | |
| JP2002518438A (ja) | 不安状態または鬱病による神経および行動変化の予防および/または治療のための神経保護組成物 | |
| ZA200700395B (en) | Novel formulation for L-tryptophane comprising carbidopa/benserazide | |
| CN114786647B (zh) | 口服药学立即释放组合物和用于重量减轻的治疗方法 | |
| JP2001518481A (ja) | 経口投与のためのセロトニン含有製剤及びその使用方法 | |
| US4405629A (en) | Process for increasing glycine levels in the brain and spinal cord | |
| JPH0518811B2 (cg-RX-API-DMAC7.html) | ||
| WO1997038701A1 (en) | Composition and method for the treatment of premenstrual syndrome | |
| CN118871096A (zh) | 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物 | |
| White et al. | Post-anaesthetic dental extraction analgesia: A comparison of paracetamol, codeine, caffeine (Solpadeine) and diflunisal (Dolobid) | |
| DE202025107875U1 (de) | Zusammensetzung, insbesondere zur Verwendung bei der Behandlung von Veisalgia | |
| EP0344158A1 (de) | Schmerzpräparat. | |
| AU2015202432B2 (en) | Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis | |
| BE894696A (fr) | Nouveaux medicaments a base de 9,10-dihydro-ergonine pour le traitement de l'arteriosclerose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R012 | Request for examination validly filed |